Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

42.9%

3 terminated/withdrawn out of 7 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4

3(50.0%)

N/A

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 4(3)

N/A(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06155513Not ApplicableTerminated

Omega-3 Monoglyceride Based Topic Products as Skin Prebiotics for Eczema

Role: lead

NCT06219213Not ApplicableTerminated

Glyceryl Eicosapentaenoate Based Topic Products as an Irritant-free Cream and Serum for Hydration of Sensitive Skin

Role: lead

NCT05161702Recruiting

Increased Inflammation-resolving Activity by Omega-3 Monoglycerides in Peripheral Blood Mononuclear Cells (PBMC).

Role: lead

NCT04897893Phase 4Completed

Impact of 2.0g Daily of MAG-EPA on the AA/EPA Ratio and Inflammation Biomarkers in a Healthy Population Aged of 50+.

Role: lead

NCT04159532Phase 4Completed

Comparative Study of Three Different Formulations of Omega-3 (EPA+DHA)

Role: lead

NCT03159507Phase 4Completed

Effect of Omega-3 Index on Cellular Metabolism and Quality of Life

Role: lead

NCT02518672Phase 2Terminated

Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)

Role: lead

All 7 trials loaded